- England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's BGNE Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.
- This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales.
- Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study.
- WM is a rare form of B-cell lymphoma that occurs in less than two percent of patients with non-Hodgkin lymphomas. Around 4,000 people are living with WM in the U.K.
- The NICE recommendation states that Brukinsa is considered cost-effective at a threshold of £20,000-30,000 per quality-adjusted life year.
- Also, the European Medicines Agency's Committee for Medicinal Products for Human Use backed Brukinsa approval for marginal zone lymphoma patients who have received at least one prior anti-CD20-based therapy.
- Price Action: BGNE shares closed lower by 1.45% at $154.82 on Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.